Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jun 2015
Multicenter StudyPivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Primary analysis from the pivotal ERIVANCE BCC study resulted in approval of vismodegib, a Hedgehog pathway inhibitor indicated for treatment of adults with metastatic or locally advanced basal cell carcinoma (BCC) that has recurred after surgery or for patients who are not candidates for surgery or radiation. ⋯ The 12-month update of the study confirms the efficacy and safety of vismodegib in management of advanced BCC.